Is there significant improvement in neonatal outcome after treating pPROM mothers with amnio-infusion?

The aim of this study was to determine the effects of amnio-infusion treatment on fetal and neonatal mortality and neonatal pulmonary development in women with singleton pregnancies and premature rupture of the membranes occurring at a gestational age of <26 weeks and who had severe oligohydramnios. The treated group of 45 consenting women received serial amnio-infusion and was compared with the control group of 44 women who underwent waiting treatment. Our study confirmed a higher number of live births in the treated group, especially in cases with a gestational age at rupture (GAR) of <20 weeks. Furthermore, even if GAR is an important factor for predicting pulmonary hypoplasia, amnio-infusion treatment reduces the probability of pulmonary hypoplasia. In fact, over 20 weeks, amnio-infusion treatment significantly reduces the risk of pulmonary hypoplasia even if normal lung development cannot be guaranteed.